REFERENCES
1. Apovian CM, Mechanick JI. Obesity is a disease! Curr Opin Endocrinol Diabetes Obes. 2013;20:367-8.
2. Bray GA, Kim KK, Wilding JPH. World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18:715-23.
3. De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 2019;17:169.
6. Dr. Sharma’s obesity notes. The M & Ms of obesity assessment. Available from: https://www.drsharma.ca/sharma-mnemonic-the-m-ms-of-obesity-assessment [Last accessed on 13 Oct 2023].
7. Gill MG, Majumdar A. Metabolic associated fatty liver disease: addressing a new era in liver transplantation. World J Hepatol. 2020;12:1168-81.
8. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-8.
9. Patel AV, Patel KS, Teras LR. Excess body fatness and cancer risk: a summary of the epidemiologic evidence. Surg Obes Relat Dis. 2023;19:742-5.
10. Rosen H. Is obesity a disease or a behavior abnormality? Did the AMA get it right? Mo Med. 2014;111:104-8.
11. Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45:511-20.
12. Salas XR, Hussey B.'Body size is not a choice' and deserves legal protections. Available from: https://www.medscape.com/viewarticle/993780 [Last accessed on 13 Oct 2023].
13. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-34.
14. Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg. 2015;150:931-40.
15. Schauer PR, Bhatt DL, Kirwan JP, et al. STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes. N Engl J Med. 2017;376:641-51.
16. Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326:2031-42.
17. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397:293-304.
18. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882.
19. Ahima RS, Lazar MA. The health risk of obesity--better metrics imperative. Science. 2013;341:856-8.
20. Moore EC, Pories WJ. The BMI: is it time to scratch for a more accurate assessment of metabolic dysfunction? Curr Obes Rep. 2014;3:286-90.
21. Hudda MT, Nightingale CM, Donin AS, et al. Reassessing ethnic differences in mean BMI and changes between 2007 and 2013 in English children. Obesity. 2018;26:412-9.
22. Laine C, Wee CC. Overweight and obesity: current clinical challenges. Ann Intern Med. 2023;176:699-700.
23. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18:1345-56.
24. Brethauer SA, Kim J, el Chaar M, et al; ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11:489-506.
25. Avery A, Langley-Evans SC, Harrington M, Swift JA. Setting targets leads to greater long-term weight losses and 'unrealistic' targets increase the effect in a large community-based commercial weight management group. J Hum Nutr Diet. 2016;29:687-96.
26. Grover BT, Morell MC, Kothari SN, Borgert AJ, Kallies KJ, Baker MT. Defining weight loss after bariatric surgery: a call for standardization. Obes Surg. 2019;29:3493-9.
27. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319:255-65.
28. Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319:241-54.
29. Salminen P, Grönroos S, Helmiö M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2022;157:656-66.
30. O'Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29:3-14.
31. Azagury D, Papasavas P, Hamdallah I, Gagner M, Kim J. ASMBS position statement on medium- and long-term durability of weight loss and diabetic outcomes after conventional stapled bariatric procedures. Surg Obes Relat Dis. 2018;14:1425-41.
32. Thaher O, Croner RS, Driouch J, Stroh C. Long- and short-term outcomes of bariatric surgery in 7755 patients with obesity and comorbidities. Minerva Surg. 2023;78:145-54.
33. Neuberg M, Blanchet MC, Gignoux B, Frering V. Long-term outcomes after one-anastomosis gastric bypass (OAGB) in morbidly obese patients. Obes Surg. 2020;30:1379-84.
34. Carandina S, Soprani A, Zulian V, Cady J. Long-term results of one anastomosis gastric bypass: a single center experience with a minimum follow-up of 10 years. Obes Surg. 2021;31:3468-75.
35. Sánchez-Pernaute A, Herrera MÁR, Ferré NP, et al. Long-term results of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Obes Surg. 2022;32:682-9.
36. Soong TC, Lee MH, Lee WJ, et al. Long-term efficacy of bariatric surgery for the treatment of super-obesity: comparison of SG, RYGB, and OAGB. Obes Surg. 2021;31:3391-9.
37. Musella M, Berardi G, Velotti N, Schiavone V, Vitiello A. Ten-year results of laparoscopic sleeve gastrectomy: retrospective matched comparison with laparoscopic adjustable gastric banding-is there a significant difference in long term? Obes Surg. 2021;31:5267-74.
38. Vital R, Navez J, Gunes S, et al. Long-term outcomes 10 years after laparoscopic sleeve gastrectomy: a single center retrospective analysis. Obes Surg. 2023;33:2356-60.
39. El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31:1755-66.
40. Montastier E, Chalret du Rieu M, Tuyeras G, Ritz P. Long-term nutritional follow-up post bariatric surgery. Curr Opin Clin Nutr Metab Care. 2018;21:388-93.
41. Mears R, Coulman KD, Pournaras DJ, Sharp D. Bariatric surgery: the GP's role in long-term post-bariatric surgery follow-up. Br J Gen Pract. 2021;71:248-9.
42. Chandarana K, Batterham RL. Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nat Med. 2012;18:668-9.
43. Sanches E, Timmermans M, Topal B, et al. Cardiac remodeling in obesity and after bariatric and metabolic surgery; is there a role for gastro-intestinal hormones? Expert Rev Cardiovasc Ther. 2019;17:771-90.
44. Timmermans M, Topal B, Sanches EE, et al. The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery. Minerva Endocrinol. 2022;47:449-59.
45. Holst JJ. Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent? J Intern Med. 2022;291:557-73.
46. Sista F, Abruzzese V, Clementi M, Carandina S, Cecilia M, Amicucci G. The effect of sleeve gastrectomy on GLP-1 secretion and gastric emptying: a prospective study. Surg Obes Relat Dis. 2017;13:7-14.
47. McCarty TR, Jirapinyo P, Thompson CC. Effect of sleeve gastrectomy on ghrelin, GLP-1, PYY, and GIP gut hormones: a systematic review and meta-analysis. Ann Surg. 2020;272:72-80.
48. Jirapinyo P, Jin DX, Qazi T, Mishra N, Thompson CC. A meta-analysis of GLP-1 after roux-en-y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg. 2018;28:615-26.
49. Schneider R, Kraljević M, Peterli R, et al. GLP-1 analogues as a complementary therapy in patients after metabolic surgery: a systematic review and qualitative synthesis. Obes Surg. 2020;30:3561-9.
50. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:133429.
51. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
52. Davies MJ, Bergenstal R, Bode B, et al. NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the scale diabetes randomized clinical trial. JAMA. 2015;314:687-99.
53. le Roux CW, Astrup A, Fujioka K, et al; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399-409.
54. Davies M, Færch L, Jeppesen OK, et al. STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971-84.
55. Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
56. Wadden TA, Bailey TS, Billings LK, et al. STEP 3 investigators. effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403-13.
57. Rubino D, Abrahamsson N, Davies M, et al. STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414-25.
58. Garvey WT, Batterham RL, Bhatta M, et al. STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-91.
59. Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022;23:e13435.
60. Guo X, Zhou Z, Lyu X, et al. The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022;54:458-71.
61. Garvey WT, Frias JP, Jastreboff AM, et al. SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613-26.
62. Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16.
63. Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-15.
64. ‘Staggering’ weight loss with tirzepatide. Available from: https://desang.net/2023/07/staggering-weight-loss-with-tirzepatide/ [Last accessed on 13 Oct 2023].
65. Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023;24:e13543.
66. Cotugno M, Nosso G, Saldalamacchia G, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. Acta Diabetol. 2015;52:331-6.
67. Capristo E, Panunzi S, De Gaetano A, et al. Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study. Diabetes Metab. 2018;44:235-42.
68. Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis. Obesity. 2022;30:2111-21.
69. Benotti PN, Bistrian BR. The sun is rising on a new era of pharmacotherapy for obesity: some words of caution. Surg Obes Relat Dis. 2023;19:1075-6.
70. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-76.
71. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-85.
72. Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707-15.
73. Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59:945-53.
74. Simonson DC, Halperin F, Foster K, Vernon A, Goldfine AB. Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study. Diabetes Care. 2018;41:670-9.
75. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes (ARMMS-T2D). Diabetes Care. 2022;45:1574-83.
76. Mirghani H, Altedlawi Albalawi I. Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15:31.
77. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964-73.
78. Courcoulas AP, Gallagher JW, Neiberg RH, et al. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial. J Clin Endocrinol Metab. 2020;105:866-76.
79. Solé T, Januel L, Denneval A, et al. Time impact on the antidiabetic effects of key bariatric surgeries: a network meta-analysis of randomized controlled trials with meta-regression. Surg Obes Relat Dis. 2022;18:832-45.
80. Rubino F, Nathan DM, Eckel RH, et al. Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861-77.
81. Russel SM, Valle V, Spagni G, et al. Physiologic mechanisms of type II diabetes mellitus remission following bariatric surgery: a meta-analysis and clinical implications. J Gastrointest Surg. 2020;24:728-41.
82. Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:2255-63.
83. Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22:335-45.
84. Alhindi Y, Avery A. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun. 2022;28:100944.
85. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65:1251-61.
86. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310-9.
87. Bethel MA, Patel RA, Merrill P, et al. EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105-13.
88. Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far? Curr Atheroscler Rep. 2022;24:867-84.
89. Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022;39:1233-48.
90. Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322:1271-82.
91. Ghiassi S, Morton JM. Safety and efficacy of bariatric and metabolic surgery. Curr Obes Rep. 2020;9:159-64.
92. Daigle CR, Brethauer SA, Tu C, et al. Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis. 2018;14:652-7.
93. Chen G, Zhang GX, Peng BQ, Cheng Z, Du X. Roux-En-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. Obes Surg. 2021;31:3303-11.
94. Alalwan AA, Friedman J, Park H, Segal R, Brumback B, Hartzema A. Comparative safety of sleeve gastrectomy and roux-en-y: a propensity score analysis. World J Surg. 2022;46:2715-24.
95. Balamurugan G, Leo SJ, Sivagnanam ST, et al. Comparison of efficacy and safety between Roux-en-Y gastric bypass (RYGB) vs one anastomosis gastric bypass (OAGB) vs single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): a systematic review of bariatric and metabolic surgery. Obes Surg. 2023;33:2194-209.
96. Gasmi A, Bjørklund G, Mujawdiya PK, et al. Micronutrients deficiences in patients after bariatric surgery. Eur J Nutr. 2022;61:55-67.
97. Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pract. 2022;2022:1201977.
98. Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134:5-17.
99. Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40:839-48.
100. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182:513-9.
101. Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the us food and drug administration. JAMA Intern Med. 2022;182:1104-6.
102. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384-90.
103. Dunleavy K. Novo Nordisk's GLP-1 drugs under review in Europe after reports flag possible suicide risks. Available from: https://www.fiercepharma.com/pharma/novo-nordisks-glp-1-drugs-under-review-europe-after-suicide-flags-raised [Last accessed on 13 Oct 2023].
104. Castaneda D, Popov VB, Wander P, Thompson CC. Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis. Obes Surg. 2019;29:322-33.
105. Needham BD, Funabashi M, Adame MD, et al. A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature. 2022;602:647-53.
106. Blackburn AN, Hajnal A, Leggio L. The gut in the brain: the effects of bariatric surgery on alcohol consumption. Addict Biol. 2017;22:1540-53.
107. Spaniolas K, Kasten KR, Celio A, Burruss MB, Pories WJ. Postoperative follow-up after bariatric surgery: effect on weight loss. Obes Surg. 2016;26:900-3.
108. Reiber BMM, Leemeyer AR, Bremer MJM, de Brauw M, Bruin SC. Weight loss results and compliance with follow-up after bariatric surgery. Obes Surg. 2021;31:3606-14.
109. Monfared S, Martin A, Selzer D, Butler A. Travel distance reduces follow-up compliance but has no effect on long-term weight loss success in bariatric patients. Surg Endosc. 2021;35:1579-83.
110. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab. 2009;35:544-57.
111. Exclusive: most patients using weight-loss drugs like Wegovy stop within a year, data show. Available from: https://www.healthleadersmedia.com/pharma/exclusive-most-patients-using-weight-loss-drugs-wegovy-stop-within-year-data-show [Last accessed on 13 Oct 2023].
112. What happens when newer weight loss meds are stopped? Available from: https://www.medscape.com/viewarticle/989988 [Last accessed on 13 Oct 2023].
113. Pratley R, Amod A, Hoff ST, et al. PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39-50.
114. Wilding JPH, Batterham RL, Davies M, et al. STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-64.
115. New antiobesity drugs will benefit many. Is that bad? Available from: https://www.medscape.com/viewarticle/990128 [Last accessed on 13 Oct 2023].
116. ICER publishes final evidence report and policy recommendations on treatments for obesity management. Available from: https://icer.org/news-insights/press-releases/strongicer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-forbrobesity-managementstrong/ [Last accessed on 13 Oct 2023].
117. Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare part D coverage of antiobesity medications-challenges and uncertainty ahead. N Engl J Med. 2023;388:961-3.
118. Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis. Obesity. 2023;31:1510-3.
119. Chang SH, Stoll CR, Colditz GA. Cost-effectiveness of bariatric surgery: should it be universally available? Maturitas. 2011;69:230-8.
120. Alsumali A, Eguale T, Bairdain S, Samnaliev M. Cost-effectiveness analysis of bariatric surgery for morbid obesity. Obes Surg. 2018;28:2203-14.
121. Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, Bagepally BS, Thakkinstian A. Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences. Obes Surg. 2021;31:3279-90.
122. Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22:1886-91.
123. Beam WB, Hunter Guevara LR. Hunter Guevara. Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients undergoing anesthesia. Available from: https://www.apsf.org/article/are-serious-anesthesia-risks-of-semaglutide-and-other-glp-1-agonists-under-recognized/ [Last accessed on 13 Oct 2023].
124. Blum D. People on drugs like ozempic say their ‘food noise’ has disappeared. Available from: https://www.nytimes.com/2023/06/21/well/eat/ozempic-food-noise.html [Last accessed on 13 Oct 2023].
125. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201-23.
126. Praxedes DR, Silva-Júnior AE, Macena ML, Gearhardt AN, Bueno NB. Prevalence of food addiction among patients undergoing metabolic/bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2023;24:e13529.
127. Ivezaj V, Benoit SC, Davis J, et al. Changes in alcohol use after metabolic and bariatric surgery: predictors and mechanisms. Curr Psychiatry Rep. 2019;21:85.
128. Cerón-Solano G, Zepeda RC, Romero Lozano JG, Roldán-Roldán G, Morin JP. Bariatric surgery and alcohol and substance abuse disorder: a systematic review. Cir Esp. 2021;99:635-47.
129. Koball AM, Ames G, Goetze RE. Addiction transfer and other behavioral changes following bariatric surgery. Surg Clin North Am. 2021;101:323-33.
130. Cassin S, Leung S, Hawa R, Wnuk S, Jackson T, Sockalingam S. Food addiction is associated with binge eating and psychiatric distress among post-operative bariatric surgery patients and may improve in response to cognitive behavioural therapy. Nutrients. 2020;12:2905.
131. Ivezaj V, Wiedemann AA, Grilo CM. Food addiction and bariatric surgery: a systematic review of the literature. Obes Rev. 2017;18:1386-97.
132. Could semaglutide treat addiction as well as obesity? Available from: https://www.medscape.com/viewarticle/993124 [Last accessed on 13 Oct 2023].
133. Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology. 2019;236:603-11.
134. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7:e159863.
135. Jirapinyo P, Thompson CC. How to incorporate bariatric training into your fellowship program. Gastroenterology. 2021;161:15-20.
136. Zevin B, Dedy NJ, Bonrath EM, Grantcharov TP. Comprehensive simulation-enhanced training curriculum for an advanced minimally invasive procedure: a randomized controlled trial. Surg Obes Relat Dis. 2017;13:815-24.
137. Zerrweck C, Rodríguez NR, Sánchez H, Zurita LC, Márquez M, Herrera MF. CMCOEM. Bariatric surgery in Mexico: training, practice and surgical trends. Updates Surg. 2021;73:1509-14.
138. Ospanov O. Training and certification for the bariatric and metabolic surgery specialization in kazakhstan. Obes Surg. 2023;33:368-9.
139. Blackstone R, Dimick JB, Nguyen NT. Accreditation in metabolic and bariatric surgery: pro versus con. Surg Obes Relat Dis. 2014;10:198-202.
140. Clapp B, Vo LU, Lodeiro C, et al. Late-term hiatal hernia after gastric bypass: an emerging problem. Surg Obes Relat Dis. 2020;16:471-5.
141. SCOPE. Training&Events. Available from: https://www.worldobesity.org/training-and-events/scope [Last accessed on 13 Oct 2023].
142. Fulton M, Srinivasan VN. Obesity, stigma and discrimination. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554571/ [Last accessed on 13 Oct 2023].
143. Westbury S, Oyebode O, van Rens T, Barber TM. Obesity stigma: causes, consequences, and potential solutions. Curr Obes Rep. 2023;12:10-23.
144. Garcia FK, Verkooijen KT, Veen EJ, Mulder BC, Koelen MA, Hazebroek EJ. Stigma toward bariatric surgery in the netherlands, france, and the united kingdom: protocol for a cross-cultural mixed methods study. JMIR Res Protoc. 2022;11:e36753.
145. Survodutide impresses in phase 2 weight-loss trial. Available from: https://www.medscape.com/viewarticle/993928 [Last accessed on 13 Oct 2023].
146. American diabetes association highlights novel agent retatrutide which results in substantial weight reduction in people with obesity or type 2 diabetes during late breaking symposium. Available from: https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium [Last accessed on 13 Oct 2023].
147. Triple agonist retatrutide hits new weight-loss highs. Available from: https://www.medscape.com/viewarticle/993714 [Last accessed on 13 Oct 2023].
148. New oral GLP-1 agonist for obesity, type 2 diabetes. Available from: https://www.medscape.com/viewarticle/993667 [Last accessed on 13 Oct 2023].
149. Wharton S, Blevins T, Connery L, et al. GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-88.
150. Specchia ML, Frisicale EM, Carini E, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020;20:73.
152. Knol J, Keller DS. Total mesorectal excision technique-past, present, and future. Clin Colon Rectal Surg. 2020;33:134-43.
153. Canning KL, Brown RE, Wharton S, Sharma AM, Kuk JL. Edmonton obesity staging system prevalence and association with weight loss in a publicly funded referral-based obesity clinic. J Obes. 2015;2015:619734.
154. Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9:e12323.
155. Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis. Obes Surg. 2022;32:3280-8.
156. Muratori F, Vignati F, Di Sacco G, Gavazzi L, Pellegrino D, Del Prete M. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord. 2022;27:2775-81.
